Background. Cough associated with acute respiratory tract infection (RTI) is one of the most common problems managed in primary care. Despite minimal evidence for the use of antibiotics, they continue to be prescribed at great cost and are a significant cause of emerging bacterial resistance. Objectives. To carry out a systematic review of randomized controlled trials to evaluate the effect of corticosteroid therapy in otherwise-healthy adults with acute RTI.
Introduction
Acute and subacute cough, resulting from an acute respiratory tract infection (RTI), is one of the most commonly encountered conditions in primary care. 1 Lower respiratory tract infection (LRTI) is a selflimiting illness, characterized by cough as the main symptom, along with other symptoms such as wheeze, pain on breathing, sputum production and shortness of breath. 2 Upper respiratory tract infection, also a selflimiting illness, very frequently leads to a troublesome cough. Although a cough resolving within 3 weeks has been termed acute (and one that persists to 8 weeks termed as subacute), 3 symptoms can last >3 weeks for a significant proportion of adults with acute infective cough. 1 Despite the self-limiting nature of RTIs, the cough in particular affects quality of life, disturbs sleep and is one of the most common reasons for work absenteeism. 4 Even though a wide range of different over-the-counter remedies are available, there is no good evidence that suggests that any of these have a beneficial effect 5 nor do any prescription-only treatments such as inhaled bronchodilator therapy. 6 For example, a recent Cochrane review identified only two trials assessing cough expectorants, which did show some benefit, although these trials did not appear adequately powered and were at some risk of bias. 5 As such, patients continue to attend primary care practitioners in the expectation of an effective prescribed therapy 7 and are often prescribed an antibiotic. Patients also often present after the acute illness has settled but the cough remains, posing a management problem for GPs with a lack of treatment options available. Prescribing antibiotics for RTIs accounts for 60% of all general practice antibiotic prescriptions, and the annual prescribing costs for acute cough alone in the UK exceed £22 million. 1, 8 However, accumulating evidence from the past 2 decades has shown only modest, if any, benefits and these only in the context of significant harms, 9 such as side effects, bacterial resistance, 10 unnecessary use of resources and cost. 1, 11, 12 It is not surprising then that identifying effective alternatives to antibiotics for acute RTI is a priority for the primary care research community and the National Health Service. 13 LRTI is associated with many symptoms that overlap with asthma, including (in varying combinations) cough, wheeze, shortness of breath and sputum production. Significant inflammatory changes are seen in the airways of both asthmatic and non-asthmatic patients with LRTI, and increased airway resistance is seen in healthy subjects with LRTI compared with healthy subjects without LRTI. 14, 15 Other experimental evidence suggests similar changes to bronchial epithelium in both asthmatics and non-asthmatics during RTI induced by common rhinoviruses, 16, 17 with a significant reduction in forced expiratory volume in 1 second (FEV 1 ) seen in both groups. 16 A Cochrane review did not identify any overall benefit in acute cough in adults with the use of beta-2 agonists, when they might have been expected to work in the presence of bronchial epithelial changes and reduced FEV1. 6 However, the authors do state that within some of the included trials, subgroup analyses suggested an improvement of symptom scores in patients treated with beta-2 agonists compared with patients treated with placebo in whom there was evidence of airflow obstruction. In addition, included trials that showed an overall improvement in the intervention group recruited more patients with a productive cough. Corticosteroids are widely used in the management of airflow obstruction and so would be expected to be of benefit to such a population. Subacute cough following infection is thought to occur because of a transient bronchial hyper-responsiveness. 11, 18 Such hyper-responsiveness is a feature of asthma and is successfully treated with corticosteroids. There is already good evidence that corticosteroids have a role in other RTIs, such as croup in children 19 and acute sore throat in adults. 20 Although little is known about the role of corticosteroids in acute infective cough in non-asthmatics, they are being used by some European GPs. 21 Both acute and persistent cough following an acute infection are recognized as major problems by both GPs and patients, and at present, there has been no identified effective treatment. There is an urgent need to identify novel therapeutic measures to deal with this common condition, particularly in light of growing patient expectations and growing microbial resistance. Therefore, the aim of this systematic review is to evaluate the effect of corticosteroid therapy in otherwise-healthy adults with acute or subacute cough in the absence of asthma. 
Methods

Search strategy
Eligibility
Studies were eligible for inclusion if they were placebocontrolled randomized trials of inhaled or oral corticosteroids in previously well adults (>16 years) with an RTI and acute (<3 weeks) or subacute (3-8 weeks) cough.
Studies were excluded if they had not tested participants for underlying asthma or if participants had an underlying respiratory illness; had recently used corticosteroids, antibiotics or beta-2 agonists; or had an underlying immune-compromising illness. Full details of excluded studies are shown in Table 1 .
One reviewer ran the searches and screened titles and abstracts for inclusion. Potentially relevant abstracts were then screened by a second author and included if both were in agreement. The full texts were obtained in the event of uncertainty, and any disagreements were resolved by consensus.
Data extraction and quality assessment
Study quality and risk of bias were assessed independently by two authors, with disagreements resolved by consensus. We assessed methodological quality by examining allocation concealment, randomization; comparability of groups on baseline characteristics, blinding, treatment adherence, attrition bias, and the use of a power calculation, using the tool devised by Higgins et al. 22 in the Cochrane Handbook. Data were extracted using a predefined extraction template. Study authors were contacted in the event of missing data.
Outcomes
Primary outcomes included the following: (i) severity and duration of cough score and (ii) severity and duration of other symptoms. These were measured using self-reported scoring systems or by any objective measures (e.g. ambulatory cough counts using audio-recording devices and subsequently interpreted using software packages. Secondary outcomes included adverse effects, participant satisfaction with treatment and the subsequent diagnosis of asthma.
Data analysis
Due to substantial heterogeneity and a lack of data, a narrative review of the results was presented. Mean cough scores from each study were detailed, including means of assessment, with associated P values and standard deviation (SD) values if provided. Similarly, data on other symptoms were presented, if available.
Results
Published research
Totally, 2148 citations were identified from the electronic searches. Of these, 32 were selected for further scrutiny. Four trials involving a total of 335 participants met the inclusion criteria (see Fig. 1 ). Three trials were conducted in Europe (the Netherlands, Germany and Austria) [23] [24] [25] and one in Thailand. 26 Three recruited participants from outpatient medical clinics [24] [25] [26] and one (the Netherlands) 23 from primary care. No study that did not assess participants for asthma prior to recruitment was identified.
Two trials recruited participants with a predominance of acute cough (mean duration of cough before recruitment: 16 and 14.4 days). 24, 25 One trial recruited mainly those with subacute cough (89 of 133), 23 and one recruited those exclusively with subacute cough. 26 All trials compared the use of inhaled corticosteroids against that of placebo, [23] [24] [25] [26] with one permitting complementary use of antibiotics and antihistamines in both groups. 25 The type, dose and length of corticosteroid treatment varied, as shown in Table 2 .
Cough severity
Three of the four studies assessed the effect of inhaled corticosteroid on cough score (total of 235 participants), 23, 24, 26 of which two showed statistically significant benefits for steroids: fluticasone dipropionate decreased mean cough score from 3.8 to 1.4 (SD: 0.2) versus 3.8-1.9 (SD: 0.1) in the placebo group, P = 0.012, 23 and extra-fine hydrofluoroalkane (HFA)-beclomethasone dipropionate versus placebo 24 ( Table 3 ). The latter trial reported a statistically significant improvement in the intervention group on an audio measurement of cough frequency (P = 0.047) but no difference between groups with reference to self-reported cough and symptom scores (no P value provided). 24 Two studies 23, 26 used similar cough symptom diaries, allowing pooling, which showed substantial heterogeneity and a non-significant treatment effect (meta-analysis not shown). Two of the trials 23, 24 detected benefits used high-dose inhaled corticosteroid (fluticasone dipropionate, 500 µg bd, and beclomethasone dipropionate, 400 µg bd), whereas the The intervention group was given inhaled corticosteroids; however, the control group was given an antitussive drug instead of a placebo. In addition, a substantial number of participants had a chronic cough prior to recruitment. Ribeiro M, Pereira CA, Nery LE, Beppu OS, Silva CO. High-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled study. 2007.
All participants had a chronic cough (>8 weeks).
Rytila P, Metso T, Heikkinen K et al. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. 2000.
The majority of participants had a chronic cough in this study and were suspected of having asthma. trials where no benefit was seen used a medium-level dose (beclomethasone dipropionate, 400 µg daily) and high-level dose (budesonide, 800 µg daily). No data were available regarding effects on cough duration.
Other symptoms
Two studies (235 participants) reported no differences on other symptoms or quality of life.
23,25
Smoking Two trials categorized participants as non-smokers and smokers, 23, 24 but only one trial investigated for subgroup differences. 23 This showed a differential beneficial effect for non-smokers compared with smokers (P < 0.001).
Subsequent asthma diagnoses
No studies reported the subsequent identification of asthma in participants.
Participant satisfaction and adherence to trial medication
No trials reported participant satisfaction data. Two trials reported on estimation of medication compliance, 23 ,24
Figure 1 Flow diagram of search strategy
Corticosteroids for acute and subacute cough both by weighing inhalation canisters before and after the trial period.
Adverse effects
Out of the 335 participants, one withdrew due to reported intolerance of treatment (no further details provided), one hospital admission occurred due to clinical deterioration (from control group), one participant developed oral thrush (intervention group), three participants developed a hoarse voice (both groups) and one developed a sore throat (control group).
Quality and risk of bias
The overall risk of bias for the included studies was graded as unclear. Only one study was considered at low risk of bias. 23 Full details are given in Table 4 . Most trials did not include a power calculation.
Ongoing research
Two ongoing trials looking at oral corticosteroids in persistent cough were identified; no further details were forthcoming from the authors of one study, where recruitment is reported to be complete. The other study has yet to begin recruitment.
Discussion
Summary of results
We found only four published trials, comprising 335 participants and of mixed quality, and one ongoing trial, investigating the role of inhaled corticosteroids for acute and subacute cough. The published data suggest inhaled corticosteroids may be beneficial for cough severity but not for other associated symptoms, without evidence of significant adverse effects. Nonsmokers may be more likely to benefit than smokers. No data were available regarding effects on cough duration and no completed trials of oral steroids were found.
Strengths and limitations
This is the first study to systemically search for, and summarize, the randomized, controlled-trial evidence for corticosteroids in acute and subacute cough. Where seen, the beneficial effects were independent of other treatments, such as antibiotics. All trials attempted, using various means, to exclude participants with known and unrecognized asthma and obstructive Change in verbal rating scale-no details provided Number of cough epochs at night on Day 11 (P < 0.01 at Hour 2 onwards) Table 3 Continued airway diseases. Although, in daily practice, asthma is not routinely excluded in patients presenting acutely with cough, we feel that for the purpose of identifying a possible treatment effect in non-asthmatics, it was important that the trials included did exclude an underlying asthma as the presence of such a condition could markedly affect the treatment effect. 27 We are confident that the aetiology of the cough in most trial participants was due to an acute infective cause, as in three of the four trials, one of the inclusion criteria was preceding LRTI, with the remaining trial including preceding URTI. Some trials also excluded participants who had symptoms suggestive of gastro-oesophageal reflux disease. The trials were generally of limited quality, with unclear or high risks of bias, and most were conducted from hospital outpatient departments, where patients may differ from those seen in primary care where the vast majority of acute LRTI is managed. However, this recruitment strategy may reflect differences in the set-up of health care provision in different countries, where there is less emphasis on primary care services. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in carrying out this review. 28 The limited number of trials meant that we were unable to assess publication bias using funnel plots and the included studies were underpowered to detect the rare adverse effects of corticosteroid therapy.
Comparison with existing literature
Corticosteroids have been used for many years to treat conditions associated with a heightened inflammatory state, including asthma. There is a growing body of literature showing corticosteroid benefits for other RTIs, such as acute sore throat, 20 croup 19 and even pneumonia in patients admitted to hospitals, 29 suggesting steroids may have a place in reducing the unwanted inflammatory effects associated with both minor and serious RTIs. The results of our review showing an improvement in cough in some participants using inhaled corticosteroids suggest that inflammatory processes at the level of the trachea and below are dampened down, in keeping with previous evidence already discussed. [14] [15] [16] [17] [18] Given that some benefits are also seen in patients using beta-2 agonists who have evidence of airflow obstruction, it would appear that inhaled corticosteroids may probably also confer such a benefit.
We identified one recently published review in the Cochrane Library by Johnstone et al., 30 assessing the evidence for inhaled corticosteroids in subacute and chronic cough. This review is substantially different from ours in three ways. First, participants were far more likely to have an underlying diagnosis that is not related to an acute RTI by including chronic cough, thereby increasing the heterogeneity of causes of cough. Second, the review omitted studies with participants with acute cough, therefore failing to establish the effect of corticosteroids on an acute respiratory illness. Finally, the authors did not exclude trials looking at participants with cough-variant asthma and eosinophilic bronchitis, both of which are conditions that are known to cause chronic cough and for which inhaled corticosteroids are already a recognized form of treatment. This review found the results to be inconsistent, with substantial heterogeneity between studies, prompting the need, like our review, for further primary research.
Implications for future research and clinical practice
Our review suggests that further, adequately powered research is warranted, in primary care, to further clarify the benefits and harms of corticosteroids for adults with acute and subacute cough. Because it is not clear from this review where the dose-response threshold lies, it would appear sensible to test the effects of high-dose (e.g. 40 mg prednisolone daily) oral steroids first. If no effect was seen, it would seem unlikely that even high-dose inhaled steroids would be effective. If benefits were observed, then subsequent trials to test the effects of high-and medium-dose inhaled steroids could be conducted. This evidence is needed before steroids can be recommended for the routine care of adults with acute infective cough, though this review does suggest that high-dose inhaled corticosteroids may be beneficial in some patients with cough secondary to acute LRTI, particularly if they are nonsmokers. It would also be important to see, as with beta-2 agonists from previous reviews, if there is a greater benefit in patients who have evidence of airflow obstruction.
Conclusions
There is insufficient evidence to recommend the routine use of inhaled corticosteroids for acute infective cough in adults at the current time. However, because some trials have shown benefits, it is important to replicate these benefits in further high-quality, adequately powered trials before a firm recommendation of treatment can be made.
